For the first time, AI has been used to optimise drug dosage in prostate cancer treatment. According to Professor Dean Ho, director of the Singapore Institute for Neurotechnology (SINAPSE) at the National University of Singapore (NUS), the breakthrough is groundbreaking and changes the way that cancer can be treated. The AI, dubbed CURATE.AI, was used to successfully reduce tumour size and levels of prostate-specific antigen (PSA) in a patient with prostate cancer. PSA is a protein produced by the pancreas and in high levels, it could be an indication of several benign conditions, including prostate cancer. The AI “individualises and optimises” each patient for maximum efficacy. In addition, the technology is scalable and can be used for patients across different ethnicities and even in different countries.
Written by Val Alvern Ligo